High potency active pharmaceutical ingredients are molecules widely used in the production of hormonal drugs which are used for the treatment of breast cancer. It is also used in the central nervous system drugs, cardiovascular drugs, and musculoskeletal drugs. Moreover, recently they have been also gaining demand in the gynecology & cosmetics industry. These drugs are segmented into innovative and generic.
The growing prevalence of cancer is predominantly fueling the market growth of the high potency active pharmaceutical ingredients. The increasing number of the pharmaceutical industry coupled with the growing investment in the research and development activities conducted by the pharmaceutical industry is again contributing to the market growth. Moreover, increasing use of high potency active pharmaceutical ingredients as antibody-drug conjugates as it is one of the most important and effective treatments for cancer is also projected to augment the market growth. It is also used to treat glaucoma which is further anticipated to foster the market growth of the high potency active pharmaceutical ingredients.
From the geographical point of view, North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of the chronic disease in the region. According to the National Health Council, chronic diseases affect around 133 million Americans, representing more than 40% of the total population of this country. About half of all adults have a chronic condition, and approximately 8 percent of children ages 5 to 17 were reported by their parents to have limited activities due to at least one chronic disease or disability.
Key Developments:
In September 2020, Seqens, a worldwide manufacturer of pharmaceutical ingredients, has launched a specialized production unit at its site in Villeneuve-La-Garenne, France. The $ 35 million (€ 30 million) facility will tackle the development and production of high potency active pharmaceutical ingredients (HPAPI).
In February 2020, Sanofi announced its plans to create a major European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any drug.
In June 2019, Lonza has invested in two multi-purpose production lines for HPAPI manufacturing at its Visp site in Switzerland. Lonza has also optimised capacity to improve its flexibility in existing production lines, supporting shorter time-to-market and accelerated approval timelines for partners.
Read More @ https://prnewsleader.com/tag/high-potency-active-pharmaceutical-ingredients-market-trend/
